Lung Cancer Research Review, Issue 75
In this issue:
Repotrectinib in ROS1 fusion-positive NSCLC
Adding SBRT to standard care in oligoprogressive NSCLC/breast cancer
Docetaxel + ramucirumab after platinum chemotherapy + ICI in NSCLC
First-line durvalumab in advanced and metastatic ECOG 2 NSCLC
Perioperative toripalimab + chemotherapy for resectable NSCLC
Immune-related adverse events and survival in ICI-treated metastatic NSCLC
First-line osimertinib for NSCLC with uncommon EGFR mutations
Brain metastasis risk unchanged by anti-PD-L1 in extensive-stage SCLC
Antibiotics reduce survival in ICI-treated extensive-stage SCLC
Nivolumab + ipilimumab in real-world mesothelioma patients
Expert contributor
Dr Michael Krasovitsky
Dr Michael Krasovitsky is a medical oncologist at The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney. He specialises in geriatric oncology, as well as the management of breast, lung, liver, and thyroid malignancies.
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.